Total Payments
$36,330
2024 Payments
$280.53
Companies
8
Transactions
52
Medicare Patients
778
Medicare Billing
$396,729
Payment Breakdown by Category
Consulting$25,405 (69.9%)
Research$7,489 (20.6%)
Travel$1,877 (5.2%)
Food & Beverage$1,559 (4.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $25,405 | 6 | 69.9% |
| Unspecified | $7,489 | 4 | 20.6% |
| Travel and Lodging | $1,877 | 7 | 5.2% |
| Food and Beverage | $1,559 | 35 | 4.3% |
Payments by Type
General
$28,841
48 transactions
Research
$7,489
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $31,680 | 29 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $4,147 | 11 | $0 (2024) |
| Stemline Therapeutics Inc. | $310.33 | 3 | $0 (2022) |
| Daiichi Sankyo Inc. | $69.32 | 3 | $0 (2024) |
| SERVIER PHARMACEUTICALS LLC | $61.11 | 3 | $0 (2024) |
| Astellas Pharma US Inc | $24.48 | 1 | $0 (2024) |
| Sumitomo Pharma America, Inc. | $23.36 | 1 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $15.00 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $280.53 | 12 | Daiichi Sankyo Inc. ($69.32) |
| 2023 | $206.55 | 10 | Novartis Pharmaceuticals Corporation ($153.04) |
| 2022 | $150.68 | 3 | Stemline Therapeutics Inc. ($109.42) |
| 2021 | $3,930 | 1 | Novartis Pharmaceuticals Corporation ($3,930) |
| 2020 | $5,229 | 3 | Celgene Corporation ($5,229) |
| 2019 | $5,589 | 7 | Celgene Corporation ($5,388) |
| 2018 | $8,613 | 6 | Celgene Corporation ($8,613) |
| 2017 | $12,332 | 10 | Celgene Corporation ($12,332) |
All Payment Transactions
52 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/07/2024 | Sumitomo Pharma America, Inc. | — | Food and Beverage | In-kind items and services | $23.36 | General |
| 12/06/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $15.00 | General |
| 12/04/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $30.99 | General |
| Category: Hematology | ||||||
| 11/06/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $30.26 | General |
| Category: Hematology | ||||||
| 10/24/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $26.59 | General |
| Category: Iron Deficiency Anemia | ||||||
| 09/17/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $23.29 | General |
| Category: Oncology | ||||||
| 08/21/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $24.62 | General |
| Category: Oncology | ||||||
| 08/19/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $15.59 | General |
| Category: Oncology | ||||||
| 08/06/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $20.79 | General |
| Category: ONCOLOGY | ||||||
| 07/25/2024 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $24.48 | General |
| Category: Oncology | ||||||
| 04/11/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $21.94 | General |
| Category: ONCOLOGY | ||||||
| 03/19/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $23.62 | General |
| Category: Oncology | ||||||
| 11/29/2023 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug), IDHIFA | Food and Beverage | In-kind items and services | $17.63 | General |
| Category: Oncology | ||||||
| 11/21/2023 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $25.22 | General |
| 10/18/2023 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $24.37 | General |
| 07/06/2023 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug) | Food and Beverage | In-kind items and services | $28.43 | General |
| Category: Oncology | ||||||
| 05/25/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $15.69 | General |
| Category: Hematology | ||||||
| 05/23/2023 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug) | Food and Beverage | In-kind items and services | $28.93 | General |
| Category: Oncology | ||||||
| 03/21/2023 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $20.19 | General |
| Category: Oncology | ||||||
| 03/15/2023 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug) | Food and Beverage | In-kind items and services | $22.71 | General |
| Category: Oncology | ||||||
| 03/15/2023 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug) | Food and Beverage | In-kind items and services | $5.11 | General |
| Category: Oncology | ||||||
| 03/09/2023 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug) | Food and Beverage | In-kind items and services | $18.27 | General |
| Category: Oncology | ||||||
| 12/10/2022 | Stemline Therapeutics Inc. | ELZONRIS (Drug) | Food and Beverage | In-kind items and services | $109.42 | General |
| Category: Oncology | ||||||
| 08/04/2022 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $23.02 | General |
| Category: Hematology | ||||||
| 04/12/2022 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $18.24 | General |
| Category: Hematology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| AZA PH US 2004 CL003 | Celgene Corporation | $2,533 | 1 |
| CC-5013-AML-001 | Celgene Corporation | $2,533 | 1 |
| MEDI4736-MDS-001 | Celgene Corporation | $1,488 | 1 |
| A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MEDALIST) (ACE-536-MDS-001) | Celgene Corporation | $935.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 201 | 837 | $353,400 | $95,808 |
| 2022 | 5 | 192 | 943 | $389,590 | $111,254 |
| 2021 | 4 | 212 | 875 | $374,970 | $104,078 |
| 2020 | 4 | 173 | 890 | $397,070 | $85,589 |
Total Patients
778
Total Services
3,545
Medicare Billing
$396,729
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 94 | 520 | $228,800 | $65,563 | 28.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 31 | 180 | $55,800 | $15,166 | 27.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 16 | 58 | $23,780 | $7,297 | 30.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 14 | 14 | $9,380 | $2,325 | 24.8% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Facility | 2023 | 20 | 32 | $19,200 | $2,212 | 11.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 11 | 15 | $8,700 | $1,825 | 21.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 15 | 18 | $7,740 | $1,421 | 18.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 89 | 592 | $260,480 | $78,593 | 30.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 38 | 232 | $72,180 | $20,554 | 28.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 18 | 60 | $24,600 | $6,379 | 25.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 12 | 12 | $8,040 | $2,006 | 24.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 14 | 23 | $9,890 | $2,001 | 20.2% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Facility | 2022 | 21 | 24 | $14,400 | $1,721 | 12.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 92 | 482 | $212,080 | $64,766 | 30.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 37 | 224 | $69,440 | $20,366 | 29.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 21 | 68 | $39,440 | $8,683 | 22.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 20 | 47 | $20,210 | $4,323 | 21.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 20 | 20 | $13,400 | $3,459 | 25.8% |
| 38222 | Diagnostic aspirations and biopsies of bone marrow | Facility | 2021 | 22 | 34 | $20,400 | $2,481 | 12.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 67 | 572 | $251,680 | $58,220 | 23.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 23 | 87 | $50,460 | $9,078 | 18.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 25 | 73 | $22,630 | $5,402 | 23.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 21 | 72 | $30,960 | $5,329 | 17.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 20 | 54 | $22,140 | $5,188 | 23.4% |
| 38222 | Bone marrow biopsy and aspiration | Facility | 2020 | 17 | 32 | $19,200 | $2,372 | 12.4% |
About Dr. Lewis Silverman, MD
Dr. Lewis Silverman, MD is a Medical Oncology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1033137864.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lewis Silverman, MD has received a total of $36,330 in payments from pharmaceutical and medical device companies, with $280.53 received in 2024. These payments were reported across 52 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($25,405).
As a Medicare-enrolled provider, Silverman has provided services to 778 Medicare beneficiaries, totaling 3,545 services with total Medicare billing of $396,729. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location New York, NY
- Active Since 07/18/2006
- Last Updated 02/22/2019
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1033137864
Products in Payments
- REBLOZYL (Biological) $5,347
- Revlimid (Drug) $5,034
- Vidaza (Drug) $2,533
- Durvalumab (Drug) $1,488
- Reblozyl (Drug) $935.00
- ELZONRIS (Drug) $310.33
- PROMACTA (Drug) $103.45
- SCEMBLIX (Drug) $63.83
- Tibsovo (Drug) $61.11
- Vanflyta (Drug) $42.73
- INJECTAFER (Drug) $26.59
- Xospata (Drug) $24.48
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in New York
Craig Thompson, Md, MD
Medical Oncology — Payments: $2.1M
Medical Oncology $2.1M
Andrew Seidman, Md, MD
Medical Oncology — Payments: $1.7M
Medical Oncology $1.7M
Dr. Joshua Richter, M.d, M.D
Medical Oncology — Payments: $1.6M
Medical Oncology $1.6M
Ghassan Abou-Alfa, Md, MD
Medical Oncology — Payments: $1.2M
Medical Oncology $1.2M
Edward Gelmann
Medical Oncology — Payments: $944,679
Medical Oncology $944,679
Miguel Perales, Md, MD
Medical Oncology — Payments: $759,555
Medical Oncology $759,555